Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

- The subjects were Japanese patients with T2DM with a BMI ≥ 25 kg/m2 or fatty liver.
- A prospective, 24-week, single-center, open-label comparative study enrolled.
- Treatment with sitagliptin or glimepiride reduced HbA1c and GA similarly.
- After 24 weeks, only sitagliptin decreased IHL and total body fat mass.

AimsTo evaluate the effect of the DPP-4 inhibitor sitagliptin on intrahepatic lipid (IHL) content and body fat in overweight Japanese patients with type 2 diabetes.MethodsA prospective, 24-week, single-center, open-label comparative study enrolled 20 Japanese patients with type 2 diabetes (male: 11, female: 9) with a BMI ≥ 25 kg/m2 or fatty liver. Subjects were randomly assigned to receive treatment with sitagliptin (25 mg titrated up to 50 mg: S) or glimepiride (0.5 mg titrated up to 1 mg: G). After starting each treatment, IHL and total fat mass were evaluated by 1H-magnetic resonance spectroscopy (1H-MRS) and dual energy X-ray absorptiometry (DEXA), respectively at baseline and at 12 weeks and 24 weeks.ResultsAfter 24 weeks, HbA1c levels showed a similar significant decrease in both groups from 7.2 (7.0, 7.5) to 6.6 (6.4, 6.8)%, (54 (53, 56) to 48(47, 49) mmol/mol) with S and 7.3(6.8, 7.4) to 6.6 (6.3, 6.7)%, (55 (51, 56) to 48 (46, 49) mmol/mol) with G, median (interquartile range), p < 0.05 vs. baseline, with no significant differences between the two groups. The IHL and total body fat mass were decreased in S group from 24.5(18.9, 36.6) to 20.5 (14.6, 28.5)% (p = 0.009) and 22.5 (20.6, 33.7) to 21.6 (19.7, 32.4)kg (p = 0.028), respectively, but not in G group.ConclusionsOur findings indicate that sitagliptin and glimepiride achieved similar glycemic control, but only sitagliptin reduced IHL and total body fat (UMIN: 000013356).